Flu Pandemic Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults
Conditions:   Pandemic Influenza;   Influenza A Virus Infection;   Orthomyxoviridae InfectionsInterventions:   Biological: A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant;   Biological: A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant;   Biological: A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant;   Biological: A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant;   Biological: A/H5N1 inactivated, split-virion influenza vaccineSponsors:   Sanofi;   Sanofi Pasteur, a Sanofi CompanyCompleted - verified January 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2007 Category: Research Source Type: clinical trials